In the past week, INKT stock has gone down by -5.75%, with a monthly gain of 30.77% and a quarterly surge of 26.68%. The volatility ratio for the week is 14.02%, and the volatility levels for the last 30 days are 16.64% for MiNK Therapeutics Inc The simple moving average for the past 20 days is 25.68% for INKT’s stock, with a 1.88% simple moving average for the past 200 days.
Is It Worth Investing in MiNK Therapeutics Inc (NASDAQ: INKT) Right Now?
Additionally, the 36-month beta value for INKT is 0.06. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for INKT is 9.92M and currently, short sellers hold a 1.24% ratio of that float. The average trading volume of INKT on January 15, 2025 was 91.30K shares.
INKT) stock’s latest price update
MiNK Therapeutics Inc (NASDAQ: INKT)’s stock price has gone rise by 9.83 in comparison to its previous close of 0.77, however, the company has experienced a -5.75% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-12-18 that Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer
INKT Trading at 21.76% from the 50-Day Moving Average
After a stumble in the market that brought INKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.26% of loss for the given period.
Volatility was left at 16.64%, however, over the last 30 days, the volatility rate increased by 14.02%, as shares surge +34.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.89% upper at present.
During the last 5 trading sessions, INKT fell by -5.75%, which changed the moving average for the period of 200-days by -6.59% in comparison to the 20-day moving average, which settled at $0.6763. In addition, MiNK Therapeutics Inc saw 21.97% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for INKT
Current profitability levels for the company are sitting at:
- 0.0 for the present operating margin
- 1.16 for the gross margin
The net margin for MiNK Therapeutics Inc stands at 0.0. The total capital return value is set at 589.07.
Based on MiNK Therapeutics Inc (INKT), the company’s capital structure generated -0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -2.36.
Currently, EBITDA for the company is -22.25 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of -0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
In conclusion, MiNK Therapeutics Inc (INKT) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
